New Therapy for Wet AMD Introduced in Switzerland by Oraya Therapeutics and EyeRAD

NEWARK, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Oraya Therapeutics, Inc. and EyeRAD announced today that agreements have been reached to establish the Vista Klinik in Basel as one of the world’s first centers to offer the Oraya Therapy™ for the treatment of wet age-related macular degeneration (AMD), the leading cause of blindness in people over 65 in the Western world. The Oraya Therapy is a non-invasive, low-energy X-Ray treatment intended as a one-time procedure to reduce or eliminate the need for frequent anti-vascular endothelial growth factor (anti-VEGF) injections directly into the eye, which are costly and burdensome for patients and clinicians alike. The Oraya treatment is a simple outpatient procedure, requiring approximately 20 minutes, with no limitations on patient activities after the therapy.